Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol for a controlled clinical trial developed by consensus of an international study group: Part two: Design of the study

Inflammation Research

Volumn 50, Issue 4, 2001, Pages 187-205

  Bauhofer, A ^a   Lorenz, W ^a   Stinner, B ^a   Rothmund, M ^a   Koller, M ^a   Sitter, H ^a   Celik, I ^a   Farndon, J R ^b   Fingerhut, A ^c   Hay, J M ^d   Lefering, R ^e   Lorijn, R ^f   Nystrom P O ^g   Schafer H ^a   Schein, M ^h   Solomkin, J ⁱ   Troidl, H ^e   Volk, H D ^j   Wittmann, D H ^k   Wyatt, J ^l  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

^c CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^d HÔPITAL LOUIS MOURIER   (France)

^e UNIVERSITY OF COLOGNE   (Germany)

^f AMGEN INC   (United States)

^g LINKÖPING UNIVERSITY   (Sweden)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^j HUMBOLDT UNIVERSITY   (Germany)

^k MEDICAL COLLEGE OF WISCONSIN   (United States)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Filgrastim; McPeek recovery index; Prophylaxis; Quality of life; Study design; True endpoint

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANTIBIOTIC PROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOSTIMULATION; INFECTION RISK; PATIENT SELECTION; PLANNING; POSTOPERATIVE INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK MANAGEMENT; SURGICAL RISK;

CLINICAL PROTOCOLS; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; INFECTION CONTROL; PLACEBOS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK FACTORS;

EID: 0035028408     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050744     Document Type: Review

References (141)

1. Granulocyte colony-stimulating factor in the prevention of postoperative infection and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part one: Rationale and hypothesis
2. Granulocyte colony-stimulating factor in the prevention of postoperative infection and sub-optimal recovery from operative risk (ASA 3 and 4). Protocol of a controlled clinical trial developed by consensus of an international study group. Part three: Individual patient, complication algorithm and quality management
3. Antibiotic trials in intra-abdominal infections: A critical evaluation of study design and outcome reporting
4. Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials in intra-abdominal infection
5. General guidelines for the evaluation of new antiinfective drugs for the prophylaxis of surgical infections: Evaluation of new anti-infective drugs for surgical prophylaxis
6. American College of Cest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
7. Clinical trials in sepsis and septic shock: A scrutiny of methodology
8. Clinical trials in adult respiratory distress syndrome
9. Methodology of clinical trials in sepsis: Discussion about the trial protocol of supplemental immunoglobulin therapy in sepsis and septic shock
10. Why have new effective therapies for sepsis not developed?
11. Very large-scale, randomized, clinical trials in sepsis and septic shock
12. Sepsis trials - Intersection of investigation, regulation, funding and practice
13. Round table conference on clinical trials for the treatment of sepsis
14. Another negative clinical trial of a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatments for serious infections
15. Sepsis, sepsis syndrome, and the systemic inflammatory response syndrome (SIRS)
16. Should morbidity replace mortality as an endpoint for clinical trials in intensive care?
17. Why sepsis trials fail
18. Post hoc analyses in sepsis trials: A formula for disappointment?
19. Design, methodology and interpretation of clinical trials in shock and sepsis
20. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment
21. Search for effective immunomodulating strategies against sepsis
22. Second step: Testing outcome measurements
23. Methodological issues in the design and implementation of controlled clinical trials in severe sepsis and septic shock
24. Experimental methods: Clinical trials
25. Better reporting of randomised controlled trials: The CONSORT statement
26. HA-1A Sepsis Study Group Treatment of Gram-negative bacteriemia and septic shock with HA- 1A human monoclonal antibody against endotoxin
27. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome
28. Extracranial-intracranial bypass, one; clinical trials
29. Cardiovascular adverse effects of antibiotics in complex surgical cases
30. Surgical research around the world
31. Haematopoetic cytokines, G-CSF and abdominal surgery
32. The philosophy of clinical trial
33. Incidence and clinical importance of perioperative histamine release: Randomised study of volume loading and antihistamines after induction of anaesthesia
34. Strahlentherapie bei chirurgischen und nichtchirurgischen patienten. Therapieerwartungen, lebensqualität und arzteinschätzungen
35. Threats to double-blinding in sepsis trials: Role of expectancies toward treatment outcome
36. Outcome: Definition and methods of evaluation
37. How to choose a relevant end point
38. Symptom reporting in cancer patients - The role of negative affect and experienced social stigma
39. Discussion forum for consensus: Duration of antibiotic treatment. Introduction - The different ways to reach consensus
40. Models of evaluation in planning and standardization of surgical treatment: Sepsis as an example
41. Klinische leitlinien als teil eines umfassenden qualitätsmanagements. Analyse heterogener behandlungskonzepte der sepsis verschiedener kliniken mit hilfe computerunterstützter erstellung, logischer überprüfung und komplexitätsbewertung klinischer Algorithmen
42. Biomedical and clinimetric approaches in the cause assessment of perioperative risk: Establishment of a German ASA-classification
43. Preoperative risk assessment with the ASA-score: A prospective trial for evaluation of mortality and morbidity in different ASA-classes of 2937 patients with general surgery
44. Management of leukopenic sepsis
45. Clinical response to filgrastim (r-metHuG-CSF) in pneumonia with severe sepsis
46. Writing a scientific paper
47. Systematic follow-up: A concept for evaluation of operative results in duodenal ulcer
48. Prediction of postoperative outcome from perioperative changes of mediators in cholecystectomy - An application of Bayes' Theorem
49. Randomised study comparing a non-ionic with an ionic contrast medium in patients with malignancies: First answer with a new diagnostic approach
50. 2-prophylaxis and volume substitution with Haemaccel-35 on cardiovascular and respiratory disturbances and histamine release. Protocol of a controlled clinical trial
51. Lebensqualität als ein integraler bestandteil des qualitätsmanagement in der operativen medizin
52. Histamine receptor antagonists
53. Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis
54. Clinical applications of hematopoetic growth factors
55. A comparison of efficacy of GM-CSF and G-CSF in the therapeutic setting of chemotherapy induced neutropenia
56. Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: Analysis of survival and multisystem organ failure
57. Cytokines and progenitor cells of granulocytopoiesis in peripheral blood of patients with bacterial infections
58. Update of recommendations for the use of hematopoietic colony-stimulating factors. Evidence-based clinical practice guidelines
59. Optimizing dose and scheduling of Filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers
60. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor in the rat
61. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage
62. Filgrastim in the treatment of hospitalized patients with community acquired pneumonia (CAP)
63. Randomised placebo controlled trial of granulocyte colony-stimulating factor in diabetic foot infection
64. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo
65. Haematopoetic cell kinetics in humans treated with rGM-CSF
66. Neutrophils express the high affinity receptor for IgG (Fc gamma RI,CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor
67. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced rumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy
68. Filgrastim (rhuG-CSF) enhances ciprofloxacin uptake and bactericidal activity of human neutrophils in vitro
69. The effect of quinolones on human hematopoietic progenitors and on cytokine production by mononuclear leucocytes
70. Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endotoxin
71. Granulocyte colony-stimulating factor and platelet aggregation
72. Recombinant human granulocyte colony-stimulating factor in the management of cancer patients: Five years on
73. Methods of randomization
74. Significant risk factors in elective colorectal surgery
75. Outcome of patients with abdominal sepsis treated in an intensive care unit
76. Postoperative morbidity and mortality following resection of the colon and rectum for cancer
77. APACHE II: A severity of disease classification system
78. What determines prognosis in sepsis? Evidence for a comprehensive individual patient risk assessment approach to the design and analysis of clinical trials
79. The performance of intensive care units: Does good management make a difference?
80. Forecasting survival in the medical intensive care unit: A comparison of clinical prognoses with formal estimates
81. The analysis of covariance
82. Powerful placebo: The dark side of the randomised trial
83. Measuring outcome from anaesthesia and operation
84. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study
85. Improving intensive care: Observations based on organizational case studies in nine intensive care units: A prospective, multicentre study
86. Auditing perioperative mortality
87. Circadian variation in unexpected postoperative death
88. Anaesthetics, coronary artery disease and outcome: Unresolved controversies
89. Perioperative cardiac morbidity
90. Long-term cardiac prognosis following noncardiac surgery
91. Prospective risk assessment: Many studies, few solutions. Is a cardiac risk assessment paradigm possible?
92. Can ASA grade or Goldman's cardiac risk index predict peri-operative mortality? A study of 16,227 patients
93. Risk factors for cardiovascular death after elective surgery under general anaesthesia
94. Pulmonale komplikationen nach abdominalchirurgischen eingriffen. Identifizierung unterschiedlicher risikogruppen
95. The risk of infection after colon injury
96. Immunological dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS)
97. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome
98. African-American and white patients admitted to the intensive care unit: Is there a difference in the therapy and outcome?
99. Comparison of the rating scale and the standard gamble in measuring patient preferences for outcomes of gallstone disease
100. Einflußgrößen der postoperativen wiederherstellung nach kolon- und rektumoperationen
101. Laparoskopische oder konventionelle kolorektale resektion - Beeinflußt die operations-technik die postoperative lebensqualität?
102. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology
103. The European Organization for Research on Treatment of Cancer approach to developing questionnaire modules. An update and overview
104. Quality of life research in patients with rectal cancer: Traditional approaches versus a problem-solving oriented perspective
105. Lebensqualität: Ein relevanter endpunkt in der chirurgie
106. Health as a theoretical concept
107. Health
108. Expectations and quality of life of cancer patients undergoing radiotherapy
109. Health complaints, stress, and distress: Exploring the central role of negative affectivity
110. Development and validation of brief measures of positive and negative affect: The PANAS scales
111. Die erfassung und dokumentation der lebensqualität nach tumortherapie
112. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy
113. Quality of life and affect in later life
114. Biostatistical aspects of outcome evaluation using TISS
115. Therapeutic Intervention Scoring System: A method for quantitative comparison of patient care
116. Therapeutic Intervention Scoring System: Update 1983
117. Nicht optimale wiederherstellungsergebnisse in der gallenchirurgie: Ein ergebnis der interaktion von belastung des neuroendokriniums, mastzellaktivierung und modulierung des immunsystems
118. Konventionelle cholecystectomie im höheren alter - Verändert der mediator histamin das outcome?
119. Simplified Therapeutic Intervention Scoring System: The TISS-28 items - Results from a multicenter study
120. Nine equivalents of nursing manpower use score (NEWS)
121. Measuring postoperative complications in general surgery patients using an outcomes-based strategy; comparison with complications presented at morbidity and mortality rounds
122. Qualitative research
123. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment
124. The systemic inflammatory response syndrome: Definitions and aetiology
125. Relationships between plasma cytokine concentrations and leukocyte functional antigen expression on patients with sepsis
126. On closed testing procedures with special reference to ordered analysis of variance
127. Supplemental immunoglobulin therapy in sepsis and septic shock - Comparison of mortality under treatment with polyvalent i.v. immunoglobulin versus placebo. Protocol of a multicenter, randomised, prospective, double-blind trial
128. How can medical journals help prevent poor medical research? Some opportunities presented by electronic publishing
129. How can journals help to prevent poor research?